UK Biosimulation Market (2026-2031)
The UK Biosimulation Market was valued at $207.6 Million in 2026 and projected to reach to $485.8 Million by 2031, representing a compound annual growth rate of 18.5%. The UK biosimulation market is poised for substantial expansion, growing from £207.6 million in 2026 to £485.8 million by 2031.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
UK Biosimulation Market Trends and Insights
- The UK's advanced pharmaceutical infrastructure and strong regulatory framework are driving adoption of biosimulation technologies across drug development pipelines.
- The UK's investment in digital health and computational biology is positioning the country as a key hub for biosimulation innovation in Europe. During the 2026–2031 forecast period, the UK biosimulation market will benefit from increased R&D spending by major pharmaceutical companies and growing demand for cost-effective drug development solutions.
- The UK's emphasis on precision medicine and personalized therapeutics is accelerating the integration of biosimulation tools into clinical workflows.
- By 2031, the UK is expected to capture significant market share as regulatory bodies increasingly recognize biosimulation as a critical component of modern drug approval processes..
Key Market Statistics
- CAGR (2026-2031) 18.5% CAGR
- Market Size, 2026 ~USD 207.6 Million
- Forecast, 2031 ~USD 485.8 Million
- Country UK
UK Biosimulation Market Overview
Strong Market Valuation :
The UK biosimulation market is valued at £207.6 million in 2026, demonstrating significant investment in computational drug development technologies across the British pharmaceutical sector.
Accelerated Growth Trajectory :
With an 18.5% CAGR, the UK market is outpacing the global average of 16.7%, reflecting the country's leadership in adopting advanced biosimulation solutions for clinical trials and drug efficacy modeling.
Regulatory Excellence Driving Adoption :
The UK's robust regulatory framework and post-Brexit independent regulatory authority are incentivizing pharmaceutical companies to invest in biosimulation technologies to streamline approval processes and reduce development timelines.
Digital Health Infrastructure :
Significant UK government investment in digital health and computational biology is creating a favorable ecosystem for biosimulation adoption, attracting both domestic and international biotech firms to establish operations.
UK Biosimulation Market Dynamics
- This growth is underpinned by the UK's advanced pharmaceutical infrastructure, world-class research institutions, and commitment to digital innovation in healthcare.
- The country's regulatory independence post-Brexit has strengthened its position as a hub for innovative drug development methodologies. Key drivers include increasing adoption of computational modeling to reduce animal testing, accelerate clinical trial timelines, and optimize drug candidate selection.
- UK pharmaceutical companies and contract research organizations are increasingly leveraging biosimulation to enhance competitiveness in global markets.
- Government initiatives supporting life sciences and digital health infrastructure will continue to fuel market expansion through 2031..
Related Ecosystem
Healthcare It
Key Takeaways
- The UK biosimulation market will grow from £207.6M (2026) to £485.8M (2031), representing an 18.5% CAGR.
- The UK's regulatory environment and pharmaceutical expertise are key drivers of biosimulation adoption and market expansion.
- The UK's focus on precision medicine and personalized therapeutics is accelerating biosimulation tool integration into drug development.
- By 2031, the UK is positioned to become a leading European hub for biosimulation innovation and commercialization.
Biosimulation Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | DATA ANALYSIS & INTERPRETATION (Type) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 16.7% from 2026 to 2031 |
| Largest Segment | SOFTWARE (Offering) |
| Market Size Base Year (Billions) | ~USD 4.27 (2026) |
| Revenue Forecast (Billions) | ~USD 9.24 (2031) |
| Segments Covered | Offering, Type, Phase Of Development |
UK Biosimulation Market Report Segmentation
3 segment dimensions are covered across the global market.
By Offering
- Services
- Software
By Type
- Consulting & Advisory
- Data Analysis & Interpretation
- Implementation, Training, And Support
By Phase Of Development
- Commercial & Market Access
- Drug Discovery
- Early Clinical Development
- Late Clinical Development
- Preclinical Development
- Regulatory
UK: BIOSIMULATION MARKET, BY END USER, 2024–2031
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 14.5 | 16.8 | 19.5 | 22.7 | 26.5 | 30.9 | 36.2 | 42.4 | 16.8 |
| CONTRACT RESEARCH ORGANIZATIONS | 28.4 | 33.6 | 39.7 | 47 | 55.7 | 66.3 | 79 | 94.3 | 18.9 |
| OTHER END USERS | 11.2 | 12.9 | 14.9 | 17.2 | 19.8 | 22.9 | 26.5 | 30.6 | 15.5 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 87.7 | 103.7 | 122.9 | 145.8 | 173.3 | 206.5 | 246.5 | 294.8 | 19.1 |
| REGULATORY BODIES | 7.8 | 9.1 | 10.6 | 12.4 | 14.5 | 17.1 | 20.1 | 23.7 | 17.5 |
| TOTAL | 149.7 | 176.1 | 207.6 | 245.1 | 289.8 | 343.7 | 408.2 | 485.8 | 18.5 |
Target Audience
- UK Pharmaceutical Companies : Need UK-specific market data to assess competitive positioning, identify growth opportunities, and make informed decisions about biosimulation technology investments and R&D resource allocation.
- Contract Research Organizations (CROs) : Require detailed UK market insights to evaluate service expansion opportunities, benchmark capabilities against competitors, and develop targeted offerings for British pharmaceutical clients.
- Biosimulation Software Vendors : Seek UK market intelligence to prioritize sales efforts, identify key customer segments, understand regulatory requirements, and develop localized go-to-market strategies for the British market.
- Healthcare Investors & Private Equity : Need UK market forecasts and growth drivers to evaluate investment opportunities, assess portfolio company potential, and identify acquisition targets in the British biosimulation and digital health sectors.
- Academic & Research Institutions : Require UK market data to understand industry demand for biosimulation expertise, align research initiatives with commercial opportunities, and secure funding for computational biology programs.
Key Companies in the UK Biosimulation Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| SANOFI | France | Public Company | Pediatric and combination vaccines (polio, pertussis, Hib, hexavalent),Other vaccines (RSV, hepatitis A, typhoid, yellow fever, rabies),Immunology and inflammation therapies, |
| CERTARA | United States | Public Company | Biosimulation platforms (Simcyp, Phoenix, NLME, Pirana),Regulatory data and submission software (Pinnacle 21, GlobalSubmit, CoAuthor, Metadata Repository),Discovery and informatics solutions (Chemaxon suite, D360, design tools), |
| DASSAULT SYSTÈMES | France | Public Company | 3D Modeling (CATIA, SOLIDWORKS, GEOVIA, BIOVIA),PLM & Collaboration (ENOVIA, CENTRIC PLM, 3DEXCITE, 3DEXPERIENCE collaboration),Simulation & Manufacturing (SIMULIA, DELMIA, 3DVIA), |
| SCHRöDINGER, INC. | United States | Public Company | Software,Drug Discovery – Collaborations (e.g., Novartis),Drug Discovery – Internal Pipeline, |
| SIMULATIONS PLUS | United States | Public Company | PBPK/PKPD and biopharmaceutics software (GastroPlus, DDDPlus, MembranePlus),QSP and disease-systems platforms (DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, Thales),ADMET Predictor, MedChem Designer and discovery-oriented AI/ML tools, |
| PHYSIOMICS PLC | United Kingdom | Public Company | Oncology modeling & simulation (Virtual Tumour–centric consulting),Broader quantitative pharmacology & computational biology services,Personalized medicine technology and related analytics, |
| INSTEM PLC | United Kingdom | Private Company | Research study management software (discovery, preclinical, early clinical),Regulatory submission and SEND-compliant dataset solutions,In silico and data insights / predictive analytics, |
SANOFI
Sanofi is a French multinational pharmaceutical company founded in 1994 with 74,846 employees. As a public company, it operates globally in the development, manufacturing, and distribution of medicines and vaccines.
CERTARA
Certara is a United States-based public company founded in 2008 with 1,546 employees. It provides software and services for drug development, including modeling, simulation, and regulatory consulting.
DASSAULT SYSTÈMES
Dassault Systèmes is a French software company founded in 1981 with 25,724 employees. As a public company, it develops 3D design, simulation, and digital lifecycle management solutions for various industries.
SCHRöDINGER, INC.
Schrödinger, Inc. is a United States-based public company founded in 1990 with 850 employees. It provides computational chemistry and molecular simulation software platforms for drug discovery and materials science.
SIMULATIONS PLUS
Simulations Plus is a United States-based public company founded in 1996 with 213 employees. It develops software for drug development, including pharmacokinetic and pharmacodynamic modeling and simulation.
PHYSIOMICS PLC
Physiomics PLC is a United Kingdom-based public company founded in 2001 with 10 employees. It specializes in computational biology and systems pharmacology for drug development.
INSTEM PLC
Instem PLC is a United Kingdom-based private company founded in 1969 with 510 employees. It provides software and services for data management and analysis in preclinical and clinical research.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise UK market valuation data (£207.6M in 2026, £485.8M in 2031) with 18.5% CAGR to support investment decisions, business planning, and competitive positioning in the British biosimulation sector.
- Regulatory & Infrastructure Insights : Understand how the UK's independent regulatory framework and digital health investments are creating unique opportunities for biosimulation adoption, enabling strategic market entry and partnership development.
- Competitive Benchmarking : Compare UK market performance against global trends (16.7% global CAGR) to identify competitive advantages, market gaps, and opportunities for differentiation in the British pharmaceutical landscape.
- Stakeholder Alignment : Access UK-specific data to align internal teams, justify budget allocation, and communicate market opportunity to investors, boards, and partners focused on the British life sciences sector.
- Strategic Planning & Forecasting : Leverage 2026-2031 forecast data to develop long-term UK market strategies, identify emerging trends, and anticipate regulatory changes affecting biosimulation adoption and investment priorities.
Frequently asked questions
What is the current size of the UK biosimulation market?
The UK biosimulation market is valued at £207.6 million in 2026 and is expected to reach £485.8 million by 2031.
What is the growth rate of the UK biosimulation market?
The UK biosimulation market is projected to grow at a compound annual growth rate (CAGR) of 18.5% from 2026 to 2031.
What factors are driving growth in the UK biosimulation market?
Key drivers include the UK's advanced pharmaceutical infrastructure, strong regulatory framework, increased R&D spending, and growing adoption of precision medicine and personalized therapeutics.
How does the UK biosimulation market compare to Europe?
The UK represents a significant portion of the European biosimulation market, with its advanced regulatory environment and pharmaceutical expertise positioning it as a leading regional hub.
What is the forecast market size for the UK biosimulation market by 2031?
The UK biosimulation market is forecast to reach £485.8 million by 2031, more than doubling from its 2026 valuation of £207.6 million.
RESEARCH METHODOLOGY
This research study involved the extensive use of both primary and secondary sources. It involved the analysis of various factors affecting the industry to identify the segmentation types, industry trends, key players, the competitive landscape of market players, and key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies.
Secondary Research
This research study extensively utilized secondary sources, including directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva, as well as white papers, annual reports, and companies' house documents. The secondary research aimed to gather and analyze information for a comprehensive and commercially focused study of the biosimulation market, encompassing technical aspects and market dynamics. It also facilitated the identification of key players, market classification, industry trends, geographical markets, and significant market-related developments. Additionally, a database of prominent industry leaders was compiled through secondary research.
Primary Research
In the primary research process, various supply-side and demand-side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, engineers, and related key executives from various companies and organizations operating in the biosimulation market. Primary sources from the demand side included personnel from pharmaceutical & biotechnology companies, contract research organizations, academic & research institutes, and regulatory bodies.
A breakdown of the primary respondents is provided below:
Note: Tiers are defined based on a company’s total revenue, as of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million. Other designations include sales managers, marketing managers, and product managers.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the biosimulation market was determined after data triangulation through the two approaches mentioned below. After the completion of each approach, the weighted average of these approaches was taken based on the level of assumptions used in each approach.
Biosimulation Market : Top-Down and Bottom-Up Approach
Data Triangulation
The size of the biosimulation market was estimated through segmental extrapolation using the bottom-up approach. The methodology used is as follows: -
- Revenues for individual companies were gathered from public sources and databases.
- Shares of leading players in the biosimulation market were gathered from secondary sources to the extent available. In certain cases, shares of biosimulation businesses were ascertained after a detailed analysis of various parameters, including product portfolios, market positioning, selling price, and geographic reach & strength.
- Individual shares or revenue estimates were validated through interviews with experts.
- The total revenue in the biosimulation market was determined by extrapolating the market share data of major companies.
Market Definition
Biosimulation is a technology that employs computer-aided simulations to replicate and predict the dynamics of biological processes and systems. It uses modern computational power to analyze and model biological behavior through mathematical expressions. Biosimulation, often referred to as Computer-aided Drug Design (CADD), plays a critical role in various stages of drug discovery and development. Leveraging AI and machine learning, biosimulation enhances the evaluation of drug safety, efficacy, and interactions, ultimately streamlining clinical trial design and accelerating time-to-market for new therapeutics.
Key Stakeholders
- Clinical/Physician centers
- Biosimulation vendors
- Clinical research organizations
- Pharmaceutical/Biopharmaceutical companies
- Research & development (R&D) companies
- Business research and consulting service providers
- Medical research laboratories
- Academic medical centers/Universities/Hospitals
- Regulatory agencies
- Clinical researchers
- Accountable care organizations
- Investors and venture capitalists
Report Objectives
- To define, describe, and forecast the biosimulation market based on offering, phase of development, modality, application, therapeutic area, deployment mode, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall biosimulation market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments such as product launches & approvals, partnerships, agreements, and collaborations in the overall biosimulation market
- To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
- Company information
- Detailed analysis and profiling of additional market players (up to 5)
Regional Analysis
- Further breakdown of the Rest of Asia Pacific biosimulation market into Taiwan, New Zealand, Thailand, Singapore, Malaysia, and other countries
- Further breakdown of the Rest of Europe biosimulation market into Russia, Austria, Finland, Sweden, Turkey, Norway, Poland, Portugal, Romania, Denmark, and other countries
Get the Full Biosimulation Market Report
Full forecast, segment splits, and company analysis for all Biosimulation Market.
- US Biosimulation Market
- Canada Biosimulation Market
- Germany Biosimulation Market
- France Biosimulation Market
- Italy Biosimulation Market
- Spain Biosimulation Market
- China Biosimulation Market
- Japan Biosimulation Market
- India Biosimulation Market
- Australia Biosimulation Market
- South Korea Biosimulation Market
- Brazil Biosimulation Market
- Mexico Biosimulation Market
- Saudi Arabia Biosimulation Market
- UAE Biosimulation Market
- South Africa Biosimulation Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
